Targeting LIPA in ovarian cancer

Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes of ovarian cancer- serous carcinoma, mucinous carcinoma, endometrioid adenocarcinoma and clear cell carcinoma. These findings indicate the utility of ERX-41 in all forms of ovarian cancer and ability to overcome tumor heterogeneity in ovarian cancer. Based on these data, we will expand our indications for our phase I clinical trial with our LIPA-targeting ERX-315 to include all forms of ovarian cancer.

Link to paper: